
## **Olivier Blin**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7248738/publications.pdf Version: 2024-02-01



OLIVIED RUN

#	Article	IF	CITATIONS
1	Staphylococcus aureus Nasal Colonization: An Update on Mechanisms, Epidemiology, Risk Factors, and Subsequent Infections. Frontiers in Microbiology, 2018, 9, 2419.	1.5	303
2	Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology, 1997, 7, 125-137.	0.3	247
3	Brain morphometry reproducibility in multi-center 3T MRI studies: A comparison of cross-sectional and longitudinal segmentations. NeuroImage, 2013, 83, 472-484.	2.1	157
4	Neural bases of different cognitive strategies for facial affect processing in schizophrenia. Schizophrenia Research, 2008, 100, 191-205.	1.1	129
5	Influence of visual cues on gait in Parkinson's disease: Contribution to attention or sensory dependence?. Journal of the Neurological Sciences, 2006, 248, 192-195.	0.3	125
6	Dopaminergic Contribution to the Regulation of Emotional Perception. Clinical Neuropharmacology, 2005, 28, 228-237.	0.2	121
7	Effect of ascorbic acid in patients with Charcot–Marie–Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2009, 8, 1103-1110.	4.9	114
8	Dopaminergic modulation of the default mode network in Parkinson's disease. European Neuropsychopharmacology, 2010, 20, 784-792.	0.3	105
9	Antipsychotic and Anxiolytic Properties of Risperidone, Haloperidol, and Methotrimeprazine in Schizophrenic Patients. Journal of Clinical Psychopharmacology, 1996, 16, 38-44.	0.7	100
10	A Comparative Review of New Antipsychotics. Canadian Journal of Psychiatry, 1999, 44, 235-244.	0.9	98
11	Amygdala activity correlates with attentional bias in PTSD. Neuropsychologia, 2011, 49, 1969-1973.	0.7	88
12	Neurobiology and Clinical Pharmacology of Obsessive-Compulsive Disorder. Clinical Neuropharmacology, 2001, 24, 191-207.	0.2	68
13	Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. Neuromuscular Disorders, 2007, 17, 248-253.	0.3	67
14	Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI). Neurobiology of Aging, 2017, 53, 1-10.	1.5	59
15	Serotonin and human information processing: fluvoxamine can improve reaction time performance. Neuroscience Letters, 1997, 229, 204-208.	1.0	56
16	Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies. Clinical Pharmacokinetics, 2017, 56, 127-138.	1.6	56
17	Apomorphine-Induced Yawning in Migraine Patients. Clinical Neuropharmacology, 1991, 14, 91.	0.2	49
18	Hemodynamic, autonomic and baroreflex changes after one night sleep deprivation in healthy volunteers. Autonomic Neuroscience: Basic and Clinical, 2009, 145, 76-80.	1.4	49

#	Article	IF	CITATIONS
19	Attentional bias in post-traumatic stress disorder diminishes after symptom amelioration. Behaviour Research and Therapy, 2011, 49, 796-801.	1.6	49
20	CX3CR1 is dysregulated in blood and brain from schizophrenia patients. Schizophrenia Research, 2015, 168, 434-443.	1.1	49
21	Comparison of Certolizumab Pegol with Other Anticytokine Agents for Treatment of Rheumatoid Arthritis: A Multiple-treatment Bayesian Metaanalysis. Journal of Rheumatology, 2011, 38, 835-845.	1.0	45
22	Neuroticism Modifies Psychophysiological Responses to Fearful Films. PLoS ONE, 2012, 7, e32413.	1.1	43
23	A comparison between the effect of intentional modulations and the action of l-Dopa on gait in Parkinson's disease. Behavioural Brain Research, 1991, 45, 177-183.	1.2	42
24	Controlled Trial of 3-Day Quinine-Clindamycin Treatment versus 7-Day Quinine Treatment for Adult Travelers with Uncomplicated Falciparum Malaria Imported from the Tropics. Antimicrobial Agents and Chemotherapy, 2001, 45, 932-935.	1.4	40
25	Dopamine and human information processing: a reaction-time analysis of the effect of levodopa in healthy subjects. Psychopharmacology, 2002, 163, 62-67.	1.5	39
26	Effect of Levodopa on Healthy Volunteers' Facial Emotion Perception. Clinical Neuropharmacology, 2005, 28, 255-261.	0.2	38
27	Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated volumetry across different MRI sites and vendors. NeuroImage, 2020, 218, 116932.	2.1	38
28	Dopaminergic Modulation of Amygdala Activity During Emotion Recognition in Patients With Parkinson Disease. Journal of Clinical Psychopharmacology, 2009, 29, 548-554.	0.7	37
29	Brain T1 intensity changes after levodopa administration in healthy subjects: a voxel-based morphometry study. British Journal of Clinical Pharmacology, 2006, 62, 546-551.	1.1	36
30	Relationship between emotional experience and resilience: An fMRI study in fire-fighters. Neuropsychologia, 2013, 51, 845-849.	0.7	35
31	Pharmacokinetic and Pharmacodynamic Analysis of Sedative and Amnesic Effects of Lorazepam in Healthy Volunteers. Clinical Neuropharmacology, 2001, 24, 71-81.	0.2	34
32	Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite <scp>E</scp> uropean 3T study on healthy elderly. Human Brain Mapping, 2015, 36, 3516-3527.	1.9	34
33	Cannabis smoking impairs driving performance on the simulator and real driving: a randomized, doubleâ€blind, placeboâ€controlled, crossover trial. Fundamental and Clinical Pharmacology, 2018, 32, 558-570.	1.0	34
34	Staphylococcus aureus nasal decolonization strategies: a review. Expert Review of Anti-Infective Therapy, 2019, 17, 327-340.	2.0	34
35	Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. Journal of Alzheimer's Disease, 2019, 69, 15-35.	1.2	34
36	Childhood trauma and emotional processing circuits in schizophrenia: A functional connectivity study. Schizophrenia Research, 2017, 184, 69-72.	1.1	33

#	Article	IF	CITATIONS
37	Evidence of a Decrease in Heart Rate and Skin Conductance Responses in PTSD Patients After a Single EMDR Session. Journal of EMDR Practice and Research, 2008, 2, 51-56.	0.2	32
38	Cognitive impulsivity in Parkinson's disease patients: Assessment and pathophysiology. Movement Disorders, 2009, 24, 2316-2327.	2.2	32
39	A Double-blind, Placebo- and Flurazepam-controlled Investigation of the Residual Psychomotor and Cognitive Effects of Modified Release Zolpidem in Young Healthy Volunteers. Journal of Clinical Psychopharmacology, 2006, 26, 284-289.	0.7	29
40	Effect of trait anxiety on prefrontal control mechanisms during emotional conflict. Human Brain Mapping, 2015, 36, 2207-2214.	1.9	28
41	Brain Networks are Independently Modulated by Donepezil, Sleep, and Sleep Deprivation. Brain Topography, 2018, 31, 380-391.	0.8	27
42	Risperidone versus haloperidol for facial affect recognition in schizophrenia: Findings from a randomised study. World Journal of Biological Psychiatry, 2009, 10, 719-728.	1.3	25
43	Effects of Subanesthetic Doses of Ketamine on Sensorimotor Information Processing in Healthy Subjects. Clinical Neuropharmacology, 2002, 25, 101-106.	0.2	24
44	Amygdala Activation Modulated by Levodopa During Emotional Recognition Processing in Healthy Volunteers. Journal of Clinical Psychopharmacology, 2007, 27, 692-697.	0.7	24
45	Differential patterns of initial and sustained responses in amygdala and cortical regions to emotional stimuli in schizophrenia patients and healthy participants. Journal of Psychiatry and Neuroscience, 2010, 35, 41-48.	1.4	24
46	Modular slowing of resting-state dynamic functional connectivity as a marker of cognitive dysfunction induced by sleep deprivation. NeuroImage, 2020, 222, 117155.	2.1	24
47	Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. Magnetic Resonance Imaging, 2021, 76, 108-115.	1.0	24
48	Plasma Aβ42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. Journal of Alzheimer's Disease, 2019, 69, 37-48.	1.2	23
49	N-methyl-?-aspartate receptors and information processing: human choice reaction time under a subanaesthetic dose of ketamine. Neuroscience Letters, 2001, 303, 29-32.	1.0	22
50	An additive factor analysis of the effect of depression on the reaction time of old patients. Acta Psychologica, 2004, 117, 1-11.	0.7	22
51	Clinical spectrum and gender differences in a large cohort of Charcot–Marie–Tooth type 1A patients. Journal of the Neurological Sciences, 2014, 336, 155-160.	0.3	22
52	Orodispersible sublingual piribedil to abort OFF episodes: A single dose placeboâ€controlled, randomized, doubleâ€blind, crossâ€over study. Movement Disorders, 2010, 25, 368-376.	2.2	21
53	Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease. Current Medical Research and Opinion, 2013, 29, 23-31.	0.9	21
54	Memantine prevents reference and working memory impairment caused by sleep deprivation in both young and aged Octodon degus. Neuropharmacology, 2014, 85, 206-214.	2.0	21

#	Article	IF	CITATIONS
55	Levodopa-induced Drowsiness in Healthy Volunteers: Results of a Choice Reaction Time Test Combined with a Subjective Evaluation of Sedation. Clinical Neuropharmacology, 2001, 24, 91-94.	0.2	20
56	Acute stress disorder modifies cerebral activity of amygdala and prefrontal cortex. Cognitive Neuroscience, 2015, 6, 39-43.	0.6	19
57	Comparison of Cannabinoid Concentrations in Plasma, Oral Fluid and Urine in Occasional Cannabis Smokers After Smoking Cannabis Cigarette. Journal of Pharmacy and Pharmaceutical Sciences, 2016, 19, 411.	0.9	19
58	Use of intravenous immunoglobulins in clinical practice: data from three French university hospitals. Fundamental and Clinical Pharmacology, 2011, 25, 753-761.	1.0	18
59	Neuropsychiatric events and dolutegravir in HIV patients. Aids, 2017, 31, 1775-1777.	1.0	18
60	Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers. Journal of Alzheimer's Disease, 2019, 69, 3-14.	1.2	18
61	A Review of the Effects of Hypoxia, Sleep Deprivation and Transcranial Magnetic Stimulation on EEG Activity in Humans: Challenges for Drug Discovery for Alzheimer's Disease. Current Alzheimer Research, 2014, 11, 501-518.	0.7	18
62	Simultaneous determination of four antiepileptic drugs in human plasma samples using an ultraâ€highâ€performance liquid chromatography tandem mass spectrometry method and its application in therapeutic drug monitoring. Biomedical Chromatography, 2016, 30, 2053-2060.	0.8	17
63	Impaired cortico-limbic functional connectivity in schizophrenia patients during emotion processing. Social Cognitive and Affective Neuroscience, 2018, 13, 381-390.	1.5	17
64	Voluntary Emotion Suppression Modifies Psychophysiological Responses to Films. Journal of Psychophysiology, 2012, 26, 116-123.	0.3	17
65	An electromyographic analysis of the effect of levodopa on the response time of healthy subjects. Psychopharmacology, 2003, 165, 313-316.	1.5	16
66	Serotonin and human information processing: an electromyographic study of the effects of fluvoxamine on choice reaction time. Neuroscience Letters, 1999, 265, 143-146.	1.0	15
67	Erratum. Clinical Neuropharmacology, 2006, 29, 185.	0.2	15
68	Effect of desipramine on patients with breathing disorders in <scp>RETT</scp> syndrome. Annals of Clinical and Translational Neurology, 2018, 5, 118-127.	1.7	15
69	Pergolide. Clinical Neuropharmacology, 2005, 28, 120-125.	0.2	14
70	Relation between facial affect recognition and configural face processing in antipsychotic-free schizophrenia Neuropsychology, 2015, 29, 197-204.	1.0	14
71	Dynamic Functional Connectivity as a complex random walk: Definitions and the dFCwalk toolbox. MethodsX, 2020, 7, 101168.	0.7	14
72	Levodopa in Parkinson's Disease: A Review of Population Pharmacokinetics/Pharmacodynamics Analysis. Journal of Pharmacy and Pharmaceutical Sciences, 2017, 20, 226.	0.9	13

#	Article	IF	CITATIONS
73	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease, 2020, 74, 213-225.	1.2	13
74	Effects of dimethylaminoethanol pyroglutamate (DMAE p-Glu) against memory deficits induced by scopolamine: evidence from preclinical and clinical studies. Psychopharmacology, 2009, 207, 201-212.	1.5	12
75	Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. British Journal of Clinical Pharmacology, 2017, 83, 1039-1047.	1.1	12
76	Antidepressant adherence patterns in older patients: use of a clustering method on a prescription database. Fundamental and Clinical Pharmacology, 2017, 31, 226-236.	1.0	11
77	CSF cutoffs for MCI due to AD depend on APOEε4 carrier status. Neurobiology of Aging, 2020, 89, 55-62.	1.5	11
78	Analysis of the benefits of vitamin cocktails in treating Charcot–Marie–Tooth disease type 1A. Muscle and Nerve, 2008, 38, 1052-1054.	1.0	10
79	Pure-tone auditory thresholds are decreased in depressed people with post-traumatic stress disorder. Journal of Affective Disorders, 2010, 127, 169-176.	2.0	10
80	A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients. PLoS ONE, 2017, 12, e0169878.	1.1	10
81	Sleep deprivation and Modafinil affect cortical sources of resting state electroencephalographic rhythms in healthy young adults. Clinical Neurophysiology, 2019, 130, 1488-1498.	0.7	10
82	An Alzheimer Disease Challenge Model: 24-Hour Sleep Deprivation in Healthy Volunteers, Impact on Working Memory, and Reversal Effect of Pharmacological Intervention. Journal of Clinical Psychopharmacology, 2020, 40, 222-230.	0.7	10
83	Contrast sensitivity improvement with sulfamethoxazole and trimethoprim in a patient with Machado-Joseph disease without spasticity. Journal of the Neurological Sciences, 1994, 123, 95-99.	0.3	9
84	Pronounced effect of caprylocaproyl macrogolglycerides on nasal absorption of IS-159, a peptide serotonin 1B/1D-receptor agonist. Clinical Pharmacology and Therapeutics, 2000, 68, 114-121.	2.3	9
85	Phenobarbital in intensive care unit pediatric population: predictive performances of population pharmacokinetic model. Fundamental and Clinical Pharmacology, 2017, 31, 558-566.	1.0	9
86	Use of albumin in three French university hospitals: is prescription monitoring still useful in 2004?. Pharmacoepidemiology and Drug Safety, 2007, 16, 79-85.	0.9	8
87	Emotional Reactivity Assessment of Healthy Elderly with an Emotion-Induction Procedure. Experimental Aging Research, 2013, 39, 109-124.	0.6	8
88	Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacology. Fundamental and Clinical Pharmacology, 2017, 31, 685-694.	1.0	8
89	Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 49-58.	1.2	8
90	Effects of Lorazepam on Emotional Reactivity, Performance, and Vigilance in Subjects With High or Low Anxiety. Journal of Clinical Psychopharmacology, 2000, 20, 226-233.	0.7	8

#	Article	IF	CITATIONS
91	Risk propensity in commercial and military pilots. Aviation, Space, and Environmental Medicine, 2003, 74, 879-81.	0.6	8
92	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	1.2	7
93	Development and Validation of a Simple and Rapid Ultrahigh-Performance Liquid Chromatography Tandem Spectrometry Method for the Quantification of Hydroxychloroquine in Plasma and Blood Samples in the Emergency Context of SARS-CoV-2 Pandemic. Therapeutic Drug Monitoring, 2021, 43, 570-576.	1.0	7
94	Clinical innovation for neurodegenerative diseases. Clinical Investigation, 2012, 2, 663-665.	0.0	6
95	Long-term use of antipsychotics in community-dwelling dementia patients. International Clinical Psychopharmacology, 2017, 32, 13-19.	0.9	6
96	Low luminance contrast sensitivity: Effects of training on psychophysical and optokinetic nystagmus thresholds in man. Vision Research, 1994, 34, 1893-1899.	0.7	5
97	A study of a topiramate pre-treatment on the effects induced by a subanaesthetic dose of ketamine on human reaction time. Neuroscience Letters, 2004, 369, 99-103.	1.0	5
98	Effects of paroxetine on emotional functioning and treatment awareness: a 4-week randomized placebo-controlled study in healthy clinicians. Psychopharmacology, 2010, 207, 619-629.	1.5	5
99	A 15-day course of donepezil modulates spectral EEG dynamics related to target auditory stimuli in young, healthy adult volunteers. Clinical Neurophysiology, 2019, 130, 863-875.	0.7	5
100	Ropivacaine Wound Infiltration for Pain Management After Breast Cancer Mastectomy: A Population Pharmacokinetic Analysis. Clinical Pharmacology in Drug Development, 2018, 7, 811-819.	0.8	4
101	Convergent and Discriminant Validity of Default Mode Network and Limbic Network Perfusion in Amnestic Mild Cognitive Impairment Patients. Journal of Alzheimer's Disease, 2021, 82, 1797-1808.	1.2	4
102	Perampanel-associated self-harm ideation after dosage increase. European Journal of Clinical Pharmacology, 2018, 74, 243-244.	0.8	3
103	One Step Forward Toward a Surrogate Endpoint for Clinical Trials of Alzheimer's Disease Drugs: The Results of PharmaCog WP5 (European ADNI). Journal of Alzheimer's Disease, 2019, 69, 1-2.	1.2	3
104	Evaluation of current dosing guidance for oral rifampicin treatment in adult patients with osteoarticular infections. British Journal of Clinical Pharmacology, 2020, 86, 2319-2324.	1.1	3
105	Synaptic function as a preclinical and experimental medicine readout for disease-modifying therapy in Alzheimer's Disease. Drug Discovery Today: Therapeutic Strategies, 2013, 10, e99-e104.	0.5	2
106	Telemedicine: What Framework, What Levels of Proof, Implementation Rules. Therapie, 2014, 69, 347-354.	0.6	2
107	Comment on "Patient Reporting in the EU: Analysis of EudraVigilance Data― Drug Safety, 2017, 40, 935-936.	1.4	2
108	Population pharmacokinetic model for tumescent lidocaine in women undergoing breast cancer surgery. European Journal of Clinical Pharmacology, 2018, 74, 1309-1315.	0.8	2

#	Article	IF	CITATIONS
109	RNA therapeutics for mood disorders: current evidence toward clinical trials. Expert Opinion on Investigational Drugs, 2021, 30, 721-736.	1.9	2
110	Prolonged continuous wound infiltration with a local anaesthetic after total mastectomy: pharmacokinetics and preliminary results on postoperative pain. Anaesthesia, Critical Care & Pain Medicine, 2019, 38, 385-386.	0.6	1
111	Polyaminosteroid Analogues as Potent Antibacterial Agents Against Mupirocin- Resistant Staphylococcus aureus Strains. Anti-Infective Agents, 2020, 18, 239-244.	0.1	1
112	Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients. Expert Opinion on Pharmacotherapy, 2021, 22, 2507-2519.	0.9	1
113	Difficultés cliniques dans les maladies raresÂ: comment les leverÂ?. Presse Medicale, 2010, 39, 51-52.	0.8	0
114	Baseline CSF Aβ, Aβ/T-TAU and Aβ/P-tau distributions to classify pharmacog MCI patients. Neurobiology of Aging, 2016, 39, S30.	1.5	0